Intent Biologics

Executive Summary

Intent Biologics is a private biotechnology company headquartered in Cambridge, Massachusetts, founded in 2021 with a focus on developing first-in-class regenerative exosome-based therapeutics. The company's lead candidate, PEP Biologic™, is a topical formulation targeting chronic wounds and autoimmune skin diseases, currently in Phase 2 clinical development. With a workforce of 201-500 employees and a leadership presence in Rochester, Minnesota, Intent Biologics aims to transform the standard of care for conditions with high unmet medical need. Exosome-based therapies represent a novel modality with potential advantages in safety, delivery, and mechanism of action, positioning the company as a pioneer in regenerative medicine for dermatological indications. Despite limited public financial data and no disclosed total funding or valuation, Intent Biologics has progressed to Phase 2 trials, indicating prior successful preclinical and early clinical work. The company's pipeline remains concentrated on its lead candidate, with no other disclosed programs. Key upcoming catalysts include data readouts from ongoing Phase 2 studies and the potential initiation of additional trials. Conviction is moderate given the early stage and inherent risks of exosome-based therapies, but the clear indication focus and novel technology warrant attention.

Upcoming Catalysts (preview)

• Q4 2026Top-line Phase 2 data for PEP Biologic in chronic wounds35% success
• Q2 2027Initiation of Phase 2 trial for PEP Biologic in autoimmune skin disease70% success